Go back

Pharma industry seeks stronger IP protection in EU trade deals

Protection for intellectual property will help stop industry R&D investment moving abroad, trade body says

Europe’s pharmaceutical industry is calling on the EU to adopt stronger protections for intellectual property in the bloc’s global trade deals, saying such a move would have economic benefits and increase drug companies’ spending on R&D.

“Intellectual property rights are increasingly important for knowledge-intensive economies,” the European Federation of Pharmaceutical Industries and Associations said in a blog post it published on 11 January. It added that IP protection is “essential for the EU’s strong export performance and for attracting investment in innovation”.

This article is only available to Research Professional News subscribers. If you are a subscriber you can read the article in full on researchprofessional.com

Pivot-RP users can log in and view the article via this link.